Search Results

« Previous 12345 Next »
Viewing Page 1 of 22 | Showing Results 1 - 10 of 216

A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors

This is a phase 1b study evaluating a combination of PEGPH20 and pembrolizumab for subjects with relapsed/refractory advanced or metastatic Non...

Philip Gold, MD
Swedish Cancer Institute

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-Stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

The purpose of this study is to determine the efficacy superiority of ASP2215 and/or ASP2215 plus azacitidine versus azacitidine as measured by...

Raya Mawad, MD
Swedish Cancer Institute

Flight Attendants Medical Research Institute (FAMRI) – International Early Lung Cancer Action Program (IELCAP) Protocol

Purpose: To assess screening for lung cancer, chronic obstructive pulmonary disease (COPD), cardiac disease, and other diseases in never smokers...

Ralph Aye, M.D.
First Hill Campus

The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease

This study compares mechanical sphincter augmentation (LINX Reflux Management System) to double-dose proton pump inhibitors (PPIs) for the...

Brian Louie, MD
Swedish Cancer Institute

Reducing Health Disparities at End-of-Life

This project will test interactive, web-based training materials designed for health care providers to learn or improve cross-cultural...

Ardith Doorenbos, PhD, RN

JCV Antibody Program in patients with Relapsing MS and who are Receiving or Considering Treatment with Tysabri

Multiple Sclerosis (MS) patients taking Tysabri have an increased risk of developing Progressive Multifocal Leukoencephalopathy (PML), a type of...

Peiqing Qian, MD
Cherry Hill Campus

I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective...

Erin Ellis, M.D. and Henry Kaplan, M.D.
Swedish Cancer Institute

A study of the effectiveness and safety of Epratuzumab in Systemic Lupus Erythematosis (SLE) (EMBODY)

The primary objective of the study is to confirm the clinical effectiveness of epratuzumab in the treatment of subjects with moderate to severe...

Philip J. Mease, MD
First Hill Campus

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) (EMBODY 2)

The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus...

Philip J. Mease, MD

A Phase III Clinical Trial Evaluating DCVax®-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme

The primary objective of this study is to evaluate progression-free-survival in patients receiving DCVax-Brain to treat GBM.

Charles Cobbs, MD
« Previous 12345 Next »
Viewing Page 1 of 22 | Showing Results 1 - 10 of 216